Cargando…
Histone deacetylase 6 in cancer
Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone subst...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122547/ https://www.ncbi.nlm.nih.gov/pubmed/30176876 http://dx.doi.org/10.1186/s13045-018-0654-9 |
_version_ | 1783352676694622208 |
---|---|
author | Li, Ting Zhang, Chao Hassan, Shafat Liu, Xinyue Song, Fengju Chen, Kexin Zhang, Wei Yang, Jilong |
author_facet | Li, Ting Zhang, Chao Hassan, Shafat Liu, Xinyue Song, Fengju Chen, Kexin Zhang, Wei Yang, Jilong |
author_sort | Li, Ting |
collection | PubMed |
description | Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. Furthermore, HDAC6 also upregulates several critical factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy. Several selective HDAC6 inhibitors are currently in clinical trials for cancer treatment and bring hope for patients with malignant tumors. A fuller understanding of HDAC6 as a critical regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies. Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target. |
format | Online Article Text |
id | pubmed-6122547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61225472018-09-05 Histone deacetylase 6 in cancer Li, Ting Zhang, Chao Hassan, Shafat Liu, Xinyue Song, Fengju Chen, Kexin Zhang, Wei Yang, Jilong J Hematol Oncol Review Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. Furthermore, HDAC6 also upregulates several critical factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy. Several selective HDAC6 inhibitors are currently in clinical trials for cancer treatment and bring hope for patients with malignant tumors. A fuller understanding of HDAC6 as a critical regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies. Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target. BioMed Central 2018-09-03 /pmc/articles/PMC6122547/ /pubmed/30176876 http://dx.doi.org/10.1186/s13045-018-0654-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Li, Ting Zhang, Chao Hassan, Shafat Liu, Xinyue Song, Fengju Chen, Kexin Zhang, Wei Yang, Jilong Histone deacetylase 6 in cancer |
title | Histone deacetylase 6 in cancer |
title_full | Histone deacetylase 6 in cancer |
title_fullStr | Histone deacetylase 6 in cancer |
title_full_unstemmed | Histone deacetylase 6 in cancer |
title_short | Histone deacetylase 6 in cancer |
title_sort | histone deacetylase 6 in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122547/ https://www.ncbi.nlm.nih.gov/pubmed/30176876 http://dx.doi.org/10.1186/s13045-018-0654-9 |
work_keys_str_mv | AT liting histonedeacetylase6incancer AT zhangchao histonedeacetylase6incancer AT hassanshafat histonedeacetylase6incancer AT liuxinyue histonedeacetylase6incancer AT songfengju histonedeacetylase6incancer AT chenkexin histonedeacetylase6incancer AT zhangwei histonedeacetylase6incancer AT yangjilong histonedeacetylase6incancer |